CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Implantable Hemodynamic Monitoring for Heart Failure Patients Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial Basic Biology of Oxidative Stress and the Cardiovascular System: Part 1 of a 3-Part Series The Impact of Proximal Vessel Tortuosity on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry High-Risk Coronary Atherosclerosis Is It the Plaque Burden, the Calcium, the Lipid, or Something Else? The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure

Original Research2022 Jun 20;e13826.

JOURNAL:Eur J Clin Invest. Article Link

Prognostic implication of lipidomics in patients with coronary total occlusion undergoing PCI

Y Zhou, XD Wang, JY Qian et al. Keywords: biomarker; CTO; CAD; lipidomics; risk prediction

ABSTRACT

BACKGROUND - Predictors of prognosis in patients with coronary chronic total occlusion (CTO) undergoing elective percutaneous coronary intervention (PCI) have remained lacking. Lipidomic profiling enable researchers to associated lipid species with disease progression and may improve the prediction of cardiovascular events.


METHODS- In the present study, 781 lipids were measured by targeted lipidomic profiling in 350 individuals (50 healthy controls, 50 patients with coronary artery disease and 250 patients with CTO). L1-regularized logistic regression was used to identify lipid species associated with adverse cardiovascular events and create predicting models which were verified by 10-fold cross-validation (200 repeats). Comparisons were made between a traditional model constructed with clinical characteristics alone and a combined model built with both lipidomic data and traditional factors.


RESULTS - 24 lipid species were dysregulated exclusively in patients with CTO, most of which belonged to sphingomyelin (SM) and triacylglycerol (TAG). Compared with traditional risk factors, new model combining lipids and traditional factors had significantly improved performance in predicting adverse cardiovascular events in CTO patients after PCI (area under the curve, 0.870 vs. 0.726, p < 0.05; Akaike information criterion, 129 vs. 156; net reclassification improvement, 0.312, p < 0.001; integrated discrimination improvement, 0.244, p < 0.001). Nomogram was built based on the incorporated model and prove efficient by Kaplan-Meier method.


CONCLUSIONS - Lipidomic profiling revealed lipid species which may participated in the formation of CTO and could contribute to the risk stratification in CTO patients undergoing PCI.